News

Oct
17
2019

Aristea Therapeutics Announces the Completion of Enrollment in RIST4721-201, a Phase 2a Proof-of-Concept Study of RIST4721 for the treatment of Palmoplantar Pustulosis (PPP)

PR Newswire, San Diego – October 16, 2019 – Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company developing novel therapies to treat serious inflammatory diseases, today announced that it has completed enrollment in RIST4721-201, a Phase 2a study to evaluate the efficacy and safety of RIST4721 in patients with palmoplantar pustulosis.

Oct
15
2019

Aristea Therapeutics to Present at the 2019 BIO Investor Forum

SAN DIEGO, Oct. 15, 2019 /PRNewswire/ — Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company developing novel therapies to treat serious inflammatory diseases, today announced that the Company will present at the 2019 BIO Investor Forum being held October 22-23, 2019 in San Francisco, CA. Dr. James Mackay, President and CEO of Aristea, will present at the conference and meet with investors.

Events

Oct
22
2019

BIO Investor Forum 2019

Dates: October 22-23, 2019

Location: The Westin St. Francis, 335 Powell St, San Francisco, California, United States of America

View Event Details

For more information, click here.

Oct
16
2019

Outsourced Pharma

Dates: October 16, 2019

Location: The Alexandria at Torrey Pines, 10996 Torreyana Rd, San Diego, California, United States of America

View Event Details

For more information, click here.

Sep
18
2019

Global Genes RARE Patient Advocacy Summit

Dates: September 18 - 20

Location: 1380 Harbor Island Drive, San Diego, California, United States of America

Aristea is a proud booth exhibitor (booth #24) at Global Genes. Get in touch with us at the event!

For more information, click here.